201 related articles for article (PubMed ID: 25942384)
1. Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.
Cocito F; Ricciardelli G; Mangiacavalli S; Pompa A; Pochintesta L; Ferretti V; Ceccuzzi R; Cazzola M; Bianchi PE; Corso A
Leuk Lymphoma; 2015; 56(12):3440-1. PubMed ID: 25942384
[No Abstract] [Full Text] [Related]
2. Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
López M; Martínez Lacasa X; Martí JM; Muntañola A; Fernández M; Huertas S; Saumell S; De Diego I; Bustamante G; Mesa A; Canet M; Julià M; Vall-Llovera F
Leuk Lymphoma; 2017 Feb; 58(2):482-484. PubMed ID: 27348085
[No Abstract] [Full Text] [Related]
3. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
6. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
[No Abstract] [Full Text] [Related]
7. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
8. Foot drop in patients treated with bortezomib - a case series and review of the literature.
Vaxman I; Mauerman ML; Gatt ML; Berger T; Gertz MA
Leuk Lymphoma; 2022 Mar; 63(3):722-728. PubMed ID: 34702127
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
Kul AN; Ipek Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
[TBL] [Abstract][Full Text] [Related]
13. Sensorineural deafness: An uncommon irreversible adverse effect of bortezomib.
Anoop P; Patil CN; Joshi VS; Maurya P; Hosamani P
Indian J Cancer; 2016; 53(3):459. PubMed ID: 28244485
[No Abstract] [Full Text] [Related]
14. Bortezomib-Associated Optic Atrophy in Two Patients With Multiple Myeloma.
Chacko JG; Behbehani R; Hundley KN; Al-Fanek Y
J Neuroophthalmol; 2018 Dec; 38(4):473-475. PubMed ID: 29746371
[No Abstract] [Full Text] [Related]
15. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach.
Yang Y; Zhao B; Lan H; Sun J; Wei G
Crit Rev Oncol Hematol; 2024 May; 197():104353. PubMed ID: 38615869
[TBL] [Abstract][Full Text] [Related]
16. In vivo confocal microscopy of multiple myeloma associated crystalline keratopathy.
Busch C; Koh S; Oie Y; Ichii M; Kanakura Y; Nishida K
Am J Hematol; 2017 Jun; 92(6):593-594. PubMed ID: 28220513
[No Abstract] [Full Text] [Related]
17. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP; Wang J; Spektor TM; Bitran JD; Lutzky J; Tabbara IA; Ye JZ; Ailawadhi S; Stampleman LV; Steis RG; Moezi MM; Swift RA; Maluso TM; Udd KA; Eshaghian S; Nassir Y; Berenson JR
Support Care Cancer; 2017 Oct; 25(10):3217-3224. PubMed ID: 28455546
[TBL] [Abstract][Full Text] [Related]
18. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
[TBL] [Abstract][Full Text] [Related]
19. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
20. Active IgGκ Multiple Myeloma Presenting With Crystalline Keratopathy.
Turnbull AMJ; Karmiris E; Anderson DF
JAMA Ophthalmol; 2018 Jul; 136(7):e181505. PubMed ID: 30003243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
